IDE Antibody (F-9): sc-393887

IDE Antibody (F-9) is a mouse monoclonal IgG1 kappa light chain antibody that detects IDE protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-IDE antibody (F-9) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. Insulin degrading enzyme (IDE) plays a crucial role in regulating insulin levels by initiating insulin cleavage, which is vital for maintaining glucose homeostasis. Beyond insulin metabolism, IDE is also involved in amyloid-β peptide degradation, linking IDE to age-related neurodegenerative conditions such as Alzheimer′s disease. IDE gene, located on chromosome 10q23.3, is essential for proper balance of both glucose and amyloid peptide levels in the brain; alterations in IDE expression can lead to significant changes in these processes. Notably, IDE inhibitor bacitracin has been shown to impede degradation of both insulin and amylin, suggesting a shared proteolytic pathway. Conformational dependence of IDE′s proteolytic function indicates potential avenues for therapeutic interventions targeting diabetes, Alzheimer′s disease, and other conditions associated with dysregulation of IDE substrate proteolysis.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

IDE Antibody (F-9) References:

1. Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo.  |  Miller, BC., et al. 2003. Proc Natl Acad Sci U S A. 100: 6221-6. PMID: 12732730
2. Amyloid precursor protein (APP) and the biology of proteolytic processing: relevance to Alzheimer's disease.  |  Ling, Y., et al. 2003. Int J Biochem Cell Biol. 35: 1505-35. PMID: 12824062
3. An insulin-degrading enzyme inhibitor decreases amylin degradation, increases amylin-induced cytotoxicity, and increases amyloid formation in insulinoma cell cultures.  |  Bennett, RG., et al. 2003. Diabetes. 52: 2315-20. PMID: 12941771
4. Substrate activation of insulin-degrading enzyme (insulysin). A potential target for drug development.  |  Song, ES., et al. 2003. J Biol Chem. 278: 49789-94. PMID: 14527953
5. Targeting Insulin-Degrading Enzyme to Treat Type 2 Diabetes Mellitus.  |  Tang, WJ. 2016. Trends Endocrinol Metab. 27: 24-34. PMID: 26651592
6. Insulin-Degrading Enzyme in the Fight against Alzheimer's Disease.  |  Kurochkin, IV., et al. 2018. Trends Pharmacol Sci. 39: 49-58. PMID: 29132916
7. The insulin-degrading enzyme as a link between insulin and neuropeptides metabolism.  |  Wacławczyk, D., et al. 2021. J Enzyme Inhib Med Chem. 36: 183-187. PMID: 33401948
8. Modulation of Insulin Sensitivity by Insulin-Degrading Enzyme.  |  González-Casimiro, CM., et al. 2021. Biomedicines. 9: PMID: 33477364
9. Hydroxypyridinethione Inhibitors of Human Insulin-Degrading Enzyme.  |  Adamek, RN., et al. 2021. ChemMedChem. 16: 1775-1787. PMID: 33686743
10. Insulin-degrading enzyme: an ally against metabolic and neurodegenerative diseases.  |  Sousa, L., et al. 2021. J Pathol. 255: 346-361. PMID: 34396529
11. Insulin-degrading enzyme (IDE) as a modulator of microglial phenotypes in the context of Alzheimer's disease and brain aging.  |  Corraliza-Gomez, M., et al. 2023. J Neuroinflammation. 20: 233. PMID: 37817156
12. Overexpression of insulin degrading enzyme: cellular localization and effects on insulin signaling.  |  Seta, KA. and Roth, RA. 1997. Biochem Biophys Res Commun. 231: 167-71. PMID: 9070242

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-IDE Antibody (F-9) has 29 citations in a variety of scientific publications.

Primary antibodies like Anti-IDE Antibody (F-9) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

IDE Antibody (F-9) Specifications

Alternate Product Name: IDE

Product Clone Name: F-9

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 122-145

Epitope Target: IDE

Epitope Species: human

Product Reactivity/Detection: IDE

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 29 citations in various scientific publications

Available Conjugates/Forms for IDE Antibody (F-9): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, P: Blocking Peptide, PE: Phycoerythrin